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154Involvement of TRPV4 in Serotonin-Evoked
Scratching
Tasuku Akiyama1,2, Margaret Ivanov1, Masaki Nagamine1, Auva Davoodi1, Mirela I. Carstens1,
Akihiko Ikoma3, Ferda Cevikbas3, Cordula Kempkes3, Joerg Buddenkotte3,4, Martin Steinhoff3,4 and
E. Carstens1Several thermosensitive transient receptor potential channels (transient receptor potential vanilloid type-1, -3;
transient receptor potential cation channel, subfamily A, member 1) have been implicated in itch. In contrast,
the role of transient receptor potential vanilloid type-4 (TRPV4) in itch is unknown. Therefore, we investigated if
TRPV4, a temperature-sensitive cation channel, plays an important role in acute itch in mice. Four different
pruritogens, including serotonin (5-hydroxytryptamine [5-HT]), histamine, SLIGRL (protease-activated receptors
2/mas-related G-protein-coupled receptor C11 agonist), and chloroquine (mas-related G-protein-coupled re-
ceptor A3 agonist), were intradermally injected into mice and itch-related scratching behavior was assessed.
TRPV4 knockout mice exhibited significantly fewer 5-HT-evoked scratching bouts compared with wild-type
mice. Notably, no differences between TRPV4 knockout and wild-type mice were observed in the number
of scratch bouts elicited by SLIGRL and histamine. Pretreatment with a TRPV4 antagonist significantly attenu-
ated 5-HT-evoked scratching in vivo. Using calcium imaging in cultured primary murine dorsal root ganglion
neurons, the response of neurons after 5-HT application, but not other pruritogens, was significantly lower in
TRPV4 knockout compared with wild-type mice. A TRPV4 antagonist significantly suppressed 5-HT-evoked
responses in dorsal root ganglion cells from wild-type mice. Approximately 90% of 5-HT-sensitive dorsal
root ganglion neurons were immunoreactive for an antibody to TRPV4, as assessed by calcium imaging. These
results indicate that 5-HT-induced itch is linked to TRPV4.
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Itch can be elicited by a wide variety of chemical stimuli,
including inflammatory mediators: amines, cytokines, pro-
teases, neuropeptides, and mas-related G-protein-coupled
receptor (Mrgpr) agonists (Akiyama and Carstens, 2014).
Histamine, an inflammatory mediator, is the best-known itch
inducer and is predominantly released by mast cells and
basophils, and possibly keratinocytes (Dvorak, 1998; Inami
et al., 2013). Histamine H1 and H4 receptors play a role in
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ator, is released by mast cells, melanocytes, and platelets, to
evoke itch (Kushnir-Sukhov et al., 2007; Slominski et al.,
2003; Turetta et al., 2004). Whereas the intradermal injec-
tion of 5-HT elicits robust scratching behaviors in rodents
(Nojima and Carstens, 2003; Yamaguchi et al., 1999), either
the intradermal injection or the iontophoretic application of
5-HT elicits mild to moderate itch in humans (Hosogi et al.,
2006; Weisshaar et al., 1997, 2004). Proteases such as tryp-
sins, kallikreins, or tryptase exert pruritogenic effects through
the activation of protease-activated receptors (PARs). PAR-2 is
overexpressed in the skin of atopic dermatitis patients and its
tethered ligand, SLIGRL, evokes itch-related behaviors in
mice (Akiyama et al., 2009; Steinhoff et al., 2003). Mrgprs
have recently been linked to chemically evoked itch (Han
et al., 2013). Chloroquine, an agonist of MrgprA3, and
bovine adrenal medullary peptide 8-22, an agonist of
MrgprC11, both elicit itch. It has been reported that SLIGRL,
a tethered ligand for PAR-2, in addition acts as an agonist of
MrgprC11 (Liu et al., 2011).
Transient receptor potential (TRP) ion channels are
involved in sensory physiology including itch and pain as
well as vision, taste, olfaction, hearing, touch, and thermo-
sensation. Recent studies have revealed that several ther-
mosensitive TRP channels are implicated in itch (Akiyama
and Carstens, 2013). Transient receptor potential vanilloid
type-1 (TRPV1) is activated by noxious heat (43 C) and is
required for itch evoked by histamine and IL-31 (Cevikbas
et al., 2014; Imamachi et al., 2009). Rodent transient re-
ceptor potential cation channel, subfamily A, member 1uthors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
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(below 17e18 C; Chen et al., 2013a) and is required for itch
evoked by chloroquine, IL-31, thymic stromal lymphopoie-
tin, endothelin-1, and bile acids (Cevikbas et al., 2014; Kido-
Nakahara et al., 2014; Lieu et al., 2014; Wilson et al., 2011,
2013). Transient receptor potential vanilloid type-3 is acti-
vated by warm temperatures (33e39 C). Mice harboring a
gain-of-function mutation in transient receptor potential
vanilloid type-3 developed dermatitis accompanied by
itch behavior (Yoshioka et al., 2009). TRPV4 is another
TRP channel activated by moderately warm temperatures
(27e34 C) and is expressed in sensory neurons as well as
keratinocytes in the skin. TRPV4 mRNA was upregulated in
skin with itching burn scars (Yang et al., 2015) and with
photodermatitis (Moore et al., 2013). However, the role of
TRPV4 in itch is largely unknown. We tested if TRPV4 is
required for certain types of itch in mice and, thus, demon-
strated that TRPV4 is required for the transmission of 5-HT-
induced itch, but not of three other tested pruritogens.
RESULTS
5-HT evoked itch is dependent on TRPV4 in vivo
Scratching elicited by 5-HT, but not the other pruritogens
(histamine, SLIGRL, and chloroquine) was significantly
reduced in the rostral back model (Figure 1a). Interestingly,
chloroquine-evoked scratching was significantly enhanced in
TRPV4 knockout (TRPV4KO) mice (Figure 1a). In this study,
we did not further investigate the mechanisms underlying this
enhancement. 5-HT-elicited scratching in TRPA1KO and
TRPV1 knockout (TRPV1KO) mice was not significantly
different compared with that in wild-type (WT) mice
(Figure 1a). In the cheek model, 5-HT predominantly elicited
scratching that was significantly diminished in TRPV4KO
mice (Figure 1b). These findings suggest that 5-HT-elicted
scratching requires TRPV4 in vivo.
To confirm the role of TRPV4 in 5-HT-evoked itch, a
pharmacological approach was also used. The TRPV4Figure 1. TRPV4KO mice are insensitive to 5-HT-mediated itch. (a) Saline, histam
NH2 (PAR-2/MrgprC11 agonist, 50 mg/10 ml), or 5-HT (10 mg/10 ml) were inject
counted in WT (open bars) and TRPV4KO mice (black bars) over a 30-minute pe
but not in TRPV1KO or TRPA1KO mice. Error bars are SEM. *P < 0.05, significant
followed by the Bonferroni test, n ¼ 6 per group). (b) 5-HT (10 mg/10 ml) was in
forelimb wipes directed to the cheek were counted over 30 minutes. *P < 0.05
5-HT, 5-hydroxytryptamine (serotonin); PAR, protease-activated receptor; TRPV1
knockout; WT, wild-type.antagonist HC067047 significantly inhibited 5-HT-evoked
scratching (Figure 2). 5-HT-evoked scratching was not
significantly affected by pretreatment with the H1 histamine
receptor antagonist terfenadine, but was significantly inhibi-
ted by pretreatment with the 5-HT2 antagonist, ketanserin
(Figure 2). These results are consistent with previous reports
(Akiyama et al., 2012; Yamaguchi et al., 1999).
Calcium imaging
To investigate whether 5-HT-responsive cells express TRPV4,
calcium imaging of dorsal root ganglion (DRG) cells was
performed, followed by immunostaining. The specificity of
the TRPV4 antibody was confirmed by detecting immuno-
reactivity of TRPV4 in DRG cells of WT mice (Figure 3b), but
not TRPV4KO mice (Figure 3c, n ¼ 129). To investigate
whether 5-HT-responsive cells express TRPV4, calcium im-
aging of DRG cells was performed, followed by immuno-
staining. Eighteen percent (206 of 1,131) of all DRG cells
from WT mice were immunopositive for the TRPV4 antibody.
Of the DRG cells shown by calcium imaging to respond to 5-
HT, 93% (15 of 16) were immunopositive for TRPV4
(Figure 3a). Eighty-one percent of TRPV4-immunoreactive
DRG cells were unresponsive to 5-HT.
We compared 5-HT-evoked responses in DRG neurons
isolated from TRPV1KO, TRPA1KO, and TRPV4KO mice with
those isolated from WT mice. DRG cells isolated from
TRPV4KO mice showed a significant decrease in the propor-
tion of those that were 5-HT sensitive (2 of 112). In contrast,
there were no significant differences in the proportions of
5-HT-sensitive DRG neurons isolated from TRPA1KO mice
(26 of 423) and TRPV1KO (9 of 205) compared with those
from WT mice (10 of 202; Figure 4). DRG cells isolated
from TRPV4KO mice showed no changes in the proportions
of histamine-, chloroquine-, or SLIGRL-sensitive neurons
compared with those from WT mice (Figure 4).
A pharmacological approach was again taken to confirm
whether TRPV4 functions downstream of 5-HT receptorine (50 mg/10 ml), chloroquine (CQ, MrgprA3 agonist, 100 mg/10 ml), SLIGRL-
ed intradermally in the rostral back. Pruritogen-elicited scratch bouts were
riod. 5-HT-elicited scratching was significantly diminished in TRPV4KO mice,
difference from the WT group (unpaired t-test or one-way analysis of variance
jected intradermally into the cheek. Hindlimb scratch bouts and ipsilateral
, significant difference from the WT group (unpaired t-test, n ¼ 4 per group).
KO, TRPV1 knockout; TRPV4KO, TRPV4 knockout; TRPA1KO, TRPA1
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Figure 2. TRPV4 antagonist inhibits 5-HT-evoked scratching. Terfenadine
(histamine H1 receptor antagonist), ketanserin (5-HT2 receptor antagonist),
HC067047 (TRPV4 antagonist), or vehicle were administered ip 30 minutes
before an intradermal injection of 5-HT. 5-HT-evoked scratching was
significantly diminished in mice treated with ketanserin and HC067047. Error
bars are SEM. *P < 0.05, significant difference from the WT group (one-way
analysis of variance followed by the Bonferroni test, n ¼ 6 per group). 5-HT,
5-hydroxytryptamine (serotonin); ip, intraperitoneal; TRPV4, transient
receptor potential vanilloid type-4; WT, wild-type. Figure 3. TRPV4 is expressed in 5-HT-sensitive DRG cells. (a) Cultured DRG
cells from naive WT mice were exposed to 5-HT (100 mM) followed by high
potassium solution (HiK). Responses were measured by Fura-2 ratiometric
calcium imaging, followed by immunostaining with a TRPV4 antibody.
Bottom panels show, from left to right, pre-5-HT, post-5-HT, and post-HiK
responses, and TRPV4 immunostaining. 5-HT-sensitive DRG cells expressed
TRPV4 (yellow circles). Scale bar ¼ 50 mm. (b) Cultured DRG cells from naive
WT mice were immunostained with a TRPV4 antibody (green). Blue indicates
nuclei (DAPI). Scale bar ¼ 50 mm. (c) As in (b) for TRPV4KO mice. DAPI,
4’,6-diamidino-2-phenylindole; DRG, dorsal root ganglion; 5-HT, 5-
hydroxytryptamine (serotonin); TRPV4, transient receptor potential vanilloid
type-4; TRPV4KO, TRPV4 knockout; WT, wild-type.
T Akiyama et al.
Role of TRPV4 in Serotonin-Evoked Itch
156activation in DRG neurons. Responses of DRG neurons to 5-
HT were markedly reduced by the application of the TRPV4
antagonist (Figure 5a). Figure 5b also shows that the TRPV4
antagonist significantly reduced the mean 5-HT-evoked re-
sponses. In contrast, controls showed no decline in succes-
sive 5-HT-evoked responses (Figure 5c). The majority of
5-HT-sensitive DRG neurons responded to capsaicin (TRPV1
agonist), hypotonic solution (TRPV4 activator), and mustard
oil (TRPA1 agonist; Figure 5d), whereas 30% of 5-HT-sen-
sitive DRG cells responded to eugenol or carvacrol, agonists
of transient receptor potential vanilloid type-3 and/or TRPA1.
The majority of histamine-sensitive DRG neurons responded
to capsaicin (Figure 5e), whereas the majority of chloroquine-
sensitive DRG neurons responded to mustard oil (Figure 5f).
The majority of SLIGRL-sensitive DRG neurons responded to
both capsaicin and mustard oil (Figure 5g).
DISCUSSION
Chronic itch is the most frequent symptom in dermatology
with a significant impact on patients’ quality of life. Defining
the mediators, receptors, circuits of receptor interactions, and
signaling pathways involved in histamine-independent itch
may lead to novel therapies for this unmet medical need in
dermatological therapy. In contrast to TRPV1, transient re-
ceptor potential vanilloid type-3, and TRPA1, the role of
TRPV4 in the regulation of itch is currently unknown. Our
findings support the hypothesis that TRPV4 mediates itch
evoked by 5-HT, but not by histamine, chloroquine, or the
PAR2/MrgprA3 agonist SLIGRL. This conclusion is supported
by the following: (i) 5-HT-evoked scratching was suppressed
in mice genetically lacking TRPV4 as well as mice treated
with a TRPV4 antagonist. (ii) Calcium imaging studies of
DRG neurons provided confirming results. (iii) More thanJournal of Investigative Dermatology (2016), Volume 13690% of 5-HT-sensitive DRG cells expressed TRPV4. Given
that 5-HT is upregulated in lesional skin of atopic dermatitis,
psoriasis, and contact dermatitis (El-Nour et al., 2007; Huang
et al., 2004a, 2004b; Nordlind et al., 2008), TRPV4 antago-
nists may be useful in treating chronic itch associated with
these skin conditions.
In addition, we demonstrate that TRPV4KO mice did not
exhibit any reduction in scratching evoked by chloroquine,
histamine, or SLIGRL. It was previously reported that
histamine-evoked scratching is mediated by TRPV1 and that
chloroquine- and SLIGRL-evoked scratching requires TRPA1
(Imamachi et al., 2009; Liu et al., 2011; Wilson et al., 2011).
TRPV1 is not required for 5-HT-evoked scratching (Imamachi
et al., 2009), consistent with our present data. TRPA1 is
required for scratching evoked by a 5-HT7 agonist, but not a
5-HT2 agonist (Liu et al., 2013; Morita et al., 2015). Although
we did not observe a reduction of 5-HT-evoked scratching in
TRPA1KO mice, TRPA1 might be involved in 5-HT-evoked
itch. A previous study showed that several TRP channels
modulate itch signaling evoked by chloroquine (Than et al.,
2013). Itch evoked by 5-HT could be modulated by several
TRP channels, including TRPV4 and TRPA1.
TRPV4 expression has been demonstrated in DRG and
trigeminal ganglion neurons, and in cutaneous nerves (Chen
Figure 4. Incidence of 5-HT-sensitive DRG cells was decreased in TRPV4KO
mice. The graph plots percentages of cultured DRG cells from wild-type (WT)
(open bars) and TRPV4KO mice (black bars) that responded to 5-HT (100
mM), histamine (HIS, 100 mM), chloroquine (CQ, 300 mM), or SLIGRL-NH2
(100 mM). The percentage of 5-HT-sensitive cells was significantly lower in
DRG cells from TRPV4KO mice (*P < 0.05, Fisher’s exact test) relative to WT
DRG cells (n ¼ 112e423). In contrast, the percentages of cells responsive to
histamine, chloroquine, and SLIGRL were similar for DRG cells from WT
compared with TRPV4KO mice (n ¼ 124e266). DRG, dorsal root ganglion;
5-HT, 5-hydroxytryptamine (serotonin); TRPV4KO, TRPV4 knockout.
Figure 5. TRPV4 antagonist inhibited 5-HT-elicited responses of DRG cells. (a)
mM) three times. Responses were measured by Fura-2 ratiometric calcium imagi
response to 5-HT (middle trace). (b) Overall percent reduction by TRPV4 antagon
variance followed by the Bonferroni test; n ¼ 8). (c) Vehicle control showing no
cultured 5-HT-sensitive DRG cells from WT mice that responded to capsaicin (T
hypotonic solution (TRPV4 activator), or mustard oil (TRPA1 agonist). Most 5-HT-
for histamine-sensitive DRG neurons. Most 5-HT-sensitive cells responded to caps
chloroquine-sensitive cells responded to mustard oil (n ¼ 26). (g) Same as in (d)
capsaicin and mustard oil (n ¼ 11). DRG, dorsal root ganglion; 5-HT, 5-hydroxy
subfamily A, member 1; TRPV1, transient receptor potential vanilloid type-1; TR
potential vanilloid type-4; TRPV4KO, TRPV4 knockout; WT, wild-type.
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Suzuki et al., 2003; Vergnolle et al., 2010; Wang et al.,
2015; Yamada et al., 2009). Whereas large DRG and tri-
geminal ganglion neurons express TRPV4 (Chen et al.,
2013b; Suzuki et al., 2003), small DRG and trigeminal gan-
glion (peptidergic) neurons expressing calcitonin gene-
related peptide and/or substance P also express TRPV4 (Chen
et al., 2013b; Moore et al., 2013; Vergnolle et al., 2010). In
this study, we found that the majority of 5-HT-sensitive DRG
neurons express TRPV4. Although there is currently no direct
evidence that any type of 5-HT receptor is coupled with
TRPV4, it was reported that a 5-HT-induced Ca2þ response is
mediated by TRPV4 in pulmonary arterial smooth muscle cells
(Xia et al., 2013). 5-HT2A and 5-HT1B receptor subtypes are
presumably involved in this response (Rodat-Despoix et al.,
2008). In mouse DRG neurons, 5-HT sensitized neuronal re-
sponses to 4a-Phorbol 12,13-didecanoate, a selective TRPV4
agonist, through phospholipase C and protein kinase
C-dependent pathways (Cenac et al., 2010). These findings
imply that certain 5-HT receptors are coupled with TRPV4.
The present findings confirm that 5-HT-evoked itch is his-
tamine independent (Akiyama et al., 2012; Imamachi et al.,
2009). DRG neurons express 5-HT1B, 5-HT1D, 5-HT1F, 5-
HT2A, 5-HT3, 5-HT4, 5-HT5B, and 5-HT7 receptor subtypes
(Ohta et al., 2006). The 5-HT receptor subtypes involved in
itch are currently under investigation. We presently observedCultured DRG cells isolated from naive WT mice were exposed to 5-HT (100
ng. Application of the TRPV4 antagonist, HC067047 (1 mM), reduced the
ist. *P < 0.05, significant difference from first responses (one-way analysis of
reduction in successive 5-HT-evoked responses (n ¼ 11). (d) Percentages of
RPV1 agonist), eugenol (TRPV3 agonist), carvacrol (TRPV3/TRPA1 agonist),
sensitive cells responded to hypotonic solution (n ¼ 13e17). (e) Same as in (d)
aicin (n ¼ 16). (f) Same as in (d) for chloroquine-sensitive DRG neurons. Most
for SLIGRL-sensitive DRG neurons. Most SLIGRL-sensitive cells responded to
tryptamine (serotonin); TRPA1, transient receptor potential cation channel,
PV3, transient receptor potential vanilloid type-3; TRPV4, transient receptor
www.jidonline.org 157
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158that the 5-HT2 antagonist ketanserin abolished 5-HT-evoked
scratching, consistent with a previous study (Yamaguchi
et al., 1999). A recent study reported that a 5-HT3 antago-
nist inhibited 5-HT-evoked scratching in mice (Ostadhadi
et al., 2015). However, previous studies showed that 5-HT3
antagonists failed to inhibit 5-HT-evoked scratching in mice
and rats, and itch in humans (Nojima and Carstens, 2003;
Weisshaar et al., 1997; Yamaguchi et al., 1999), suggesting
that 5-HT3 is less likely involved in 5-HT-evoked itch. A very
recent study suggests that 5-HT7 is involved in 5-HT-evoked
itch (Morita et al., 2015). There is no report regarding the
effects of the 5-HT2 antagonist or the 5-HT7 antagonist on 5-
HT-evoked itch in humans.
TRPV4 is largely expressed in skin epidermal keratinocytes
and plays a role in epidermal barrier homeostasis (Kida et al.,
2012), inflammation, and photodermatitis-associated pain
(Moore et al., 2013). Keratinocytes also express 5-HT1A, 5-
HT1B, 5-HT2A, 5-HT2B, and 5-HT7 receptor subtypes
(Slominski et al., 2003), suggesting that 5-HT may be able to
activate keratinocytes in conjunction with TRPV4. A recent
study also reported that 5-HT stimulates IL-6 release from
primary human keratinocytes (Kaneko et al., 2009). It is thus
possible that 5-HT could activate one or more 5-HT subtypes
coupled with TRPV4, as noted above, to evoke release of
substances from keratinocytes that could act on anatomically
closely associated sensory nerve endings. A recent study
revealed that the activation of TRPV4 in keratinocytes con-
tributes to the release of endothelin-1, another important
pruitogen (Moore et al., 2013). However, endothelin-1 is
unlikely to be involved in 5-HT-evoked itch, as endothelin-1-
evoked itch is mediated by TRPA1, but not TRPV4 (Kido-
Nakahara et al., 2014).
In summary, we demonstrate that TRPV4 is involved in
histamine-independent itch associated with 5-HT, and is thus
linked to the activation of one or more 5-HT receptor sub-
types. In contrast, TRPV4 is not linked to other pruritogen
receptors for histamine, chloroquine, or PAR2/MrgprA3 ag-
onists. Further studies are demanded to fully explore to which
pruritic pathways TRPV4 is linked. Furthermore, it will be




Experiments were performed using adult male knockout mice lack-
ing TRPV4 (TRPV4KO; Grant et al., 2007; Liedtke et al., 2003),
TRPV1 (TRPV1KO), TRPA1 (TRPA1KO), and WT (littermates of
TRPV4KO mice; C57BL/6 mice; 19e34 g) under a protocol
approved by the UC Davis Animal Care and Use Committee.
Knockout mice were maintained under specific pathogen-free con-
ditions and were bred by backcrossing with C57BL/6 mice. The fur
on the rostral back or the cheek was shaved and mice were habit-
uated to the Plexiglas recording arena 1 week before testing. For
intraperitoneal injections, either terfenadine (30 mg/kg; Sigma-
Aldrich, St. Louis, MO; Akiyama et al., 2012), ketanserin (3 mg/kg;
Sigma-Aldrich; Yamaguchi et al., 1999), HC067047 (10 mg/kg;
Tocris Bioscience, Bristol, UK; Everaerts et al., 2010), or vehicle
(10% DMSO þ 10% Tween80 in saline) was administered, followed
30 minutes later by intradermal injection (10 ml) of either chloro-
quine (193 nmol; Sigma-Aldrich), histamine (271 nmol; Sigma-Journal of Investigative Dermatology (2016), Volume 136Aldrich), 5-HT (47 nmol; Sigma-Aldrich), or SLIGRL (76 nmol;
Quality Controlled Biochemicals, Hopkinton, MA). Microinjections
were made intradermal in the nape of the neck or cheek using a 30
G needle attached to a Hamilton microsyringe by PE-50 tubing.
Immediately after the intradermal injection, mice were placed into
the arena and videotaped from above for 30 minutes. Generally 3e4
mice were injected and videotaped simultaneously. Immediately
after commencing videotaping, all investigators left the room. Vid-
eotapes were reviewed by investigators blinded to the treatment, and
the number of scratch bouts was counted at 5-min intervals. A
scratch bout was defined as one or more rapid back-and-forth hind
paw motion(s) directed toward and contacting the injection site, and
ending with the licking or biting of the toes and/or the placement of
the hind paw on the floor. Hind paw movements directed away from
the injection site (e.g., ear scratching) and grooming movements
were not counted. A wipe was defined as a singular motion of the
ipsilateral, but not bilateral, forelimb beginning at the caudal extent
of the injected cheek and proceeding in a rostral direction. The inner
aspect of the ankle and/or forelimb typically contacted the cheek
with the paw closed. One-way analysis of variance followed by the
Bonferroni posttest or unpaired t-tests (two-tailed) was used to
compare the total number of scratch bouts across pretreatment
groups. In all cases P < 0.05 was considered to be significant.
Calcium imaging
Experiments were performed using adult male TRPV4KO, TRPA1KO,
TRPV1KO, and WT (C57BL/6) mice (18e34 g) under a protocol
approved by the UC Davis Animal Care and Use Committee. The
animal was euthanized under sodium pentobarbital anesthesia, and
upper- to mid-cervical DRGs were acutely dissected and enzymat-
ically digested at 37 C for 10 minutes in Hanks’ Balanced Salt
Solution (HBSS; Invitrogen, Carlsbad, CA) containing 20 U/ml
papain (Worthington Biochemical, Lakewood, NJ) and 6.7 mg/ml L-
cysteine (Sigma-Aldrich), and then again for 10 minutes at 37 C in
HBSS containing 3 mg/ml collagenase (Worthington Biochemical).
The ganglia were then mechanically triturated using fire-polished
glass pipettes. DRG cells were pelleted; suspended in MEM with
Earle’s balanced salt solution (Gibco, Life Technologies, Carlsbad,
CA) containing 100 U/ml penicillin, 100 mg/ml streptomycin (Gibco,
Life Technologies), 1 vitamin (Gibco, Life Technologies), and 10%
horse serum (Quad Five, Ryegate, MT); plated on poly-D-lysinee
coated glass coverslips; and cultured for 16e24 hours.
DRG cells were incubated in Ringer’s solution (pH 7.4, 140 mM
NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES,
and 4.54 mM NaOH) with 10 mM Fura-2 AM and 0.05% of Pluronic
F-127 (Invitrogen). Coverslips were mounted on a custom-made
aluminum perfusion block and viewed through an inverted micro-
scope (Nikon TS100, Technical Instruments, Burlingame, CA). Fluo-
rescence was excited by UV light at 340 nm and 380 nm alternately,
and the emitted light was collected via a CoolSNAP camera attached
to a Lambda LS lamp and a Lambda optical filter changer (Sutter In-
strument, Novato, CA). Ratiometric measurements were made using
SimplePCI software (Hamamatsu, Sewickley, PA) every 3 seconds.
Solutions were delivered by a solenoid-controlled eight-channel
perfusion system (ValveLink, AutoMate Scientific, San Francisco,
CA). One of the following agents was delivered: chloroquine (300
mM), histamine (100 mM), 5-HT (100 mM), and the PAR-2/MrgprA3
agonist SLIGRL-NH2 (100 mM). In some experiments, one of the
following agents was delivered after the delivery of prutiogen:
capsaicin (1 mM), eugenol (100 mM), carvacrol (100 mM), 30%
T Akiyama et al.
Role of TRPV4 in Serotonin-Evoked Itchhypotonic solution, and mustard oil (100 mM). Stimulus duration was
30 seconds (10 seconds for capsaicin). In other experiments, 5-HT
was delivered three times at 3.5-minute intervals. HC067047 (1
mM; Everaerts et al., 2010) was delivered beginning 10 seconds
before the second 5-HT application for a duration of 2 minutes.
Potassium chloride (144 mM) was always delivered at the end of
each experiment. Ratios were normalized to baseline. Cells were
judged to be sensitive if the ratio value increased by greater than
10% of the resting level after chemical application. Only cells
responsive to high potassium were included for analysis. After the
experiment, coverslips were etched with a diamond pen to provide
landmarks for alignment with subsequent immunohistofluoresent
labeling of the same cells. Fisher’s exact test was used to compare
the percentages of pruritogen-sensitive cells between groups.
Immunocytochemistry
After calcium imaging, DRG cells in the culture dish were fixed in
formalin, followed by 30% sucrose, and then incubated with 5%
normal serum. They were immunostained with a rabbit anti-TRPV4
antibody (1:300; Abcam, Cambridge, MA) at 4 C overnight, fol-
lowed by incubation with the corresponding secondary antibody
conjugated with Alexa Fluor 488 (1:500; Life Technologies, Grand
Island, NY) for 2 hours. DRG cells were counterstained with
4’,6-diamidino-2-phenylindole in the mounting medium (Vector
Laboratories, Burlingame, CA). Images were captured using a fluo-
rescence microscope (Nikon Eclipse Ti; Technical Instruments).
Immunohistofluorescent images were aligned with images captured
during calcium imaging to determine the percentages of 5-HT-
responsive DRG cells that were double labeled for TRPV4.
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